The 2016 revision of the World Health Organization (WHO) classification of lymphoid neoplasms proposed a new subtype of DLBCL, double-expressor lymphoma (DEL), which is characterized by dual overexpression of BCL2 and MYC proteins without underlying chromosomal rearrangements. Here, MYC is linked to diffuse large B-cell lymphoma.